Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2010

View Archived Issues

Pregabalin therapy correlates with mild cognitive impairment

Apixaban more effective than enoxaparin in improving thromboprophylaxis after knee replacement

Long-term agalsidase beta treatment beneficial in Fabry's disease

Wyeth discloses novel mTOR and PI3K-alpha inhibitors

New semicarbazide-sensitive amine oxidase inhibitors disclosed by Hungarian researchers

Amgen discovers novel BACE 1 inhibitors

Potent and selective Chk1/Chk2 inhibitor V-158411 potentiates irinotecan antitumor activity in vivo

Potent and selective CSF-1-R inhibitor exhibits favorable pharmacokinetics and activity in vivo

Promising preclinical data presented on DGAT-1 inhibitor PF-04620110

ChemoCentryx presents new chemokine CCR1 receptor antagonists

Auspex Pharmaceuticals claims new deuterated pyrazole carboxamide coagulation factor Xa inhibitors

Achaogen completes series C financing to fund phase II ACHN-490 trial

Cubist doses first patient in phase II CB-183315 trial in Clostridium difficile-associated diarrhea

Rexahn submits protocol for phase II Serdaxin trial in Parkinson's disease to FDA

Xanodyne and Ferring enter copromotion agreement for Zipsor in U.S.

Celgene reports on phase I PDA-001 trial in Crohn's disease

Tragara completes enrollment in phase II trial of Capoxigem in NSCLC

FDA requests additional clinical data on ProStrakan's Rectogesic

FDA recommends additional trial of Cell Therapeutics' Pixuvri for NHL

Juventas begins phase I JVS-100 trial in patients with heart failure

Can-Fite BioPharma advances CF-1021 to phase I/II in liver cancer

Keryx begins enrollment in phase III KRX-0401 trial in colorectal cancer

Pharmasset advances PSI-938 to the clinic for hepatitis C

iBio grants rights to iBioLaunch platform for development of anthrax-plague combination vaccine

Cephalon acquires Mepha and Ception Therapeutics